GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Theravance, Inc. (THRX) [hlAlert]

Rating:
Buy THRX
down 5.53 %

Theravance, Inc. (THRX) rated Buy with price target $23 by ThinkEquity

Posted on: Friday,  Feb 20, 2009  8:25 AM ET by ThinkEquity

ThinkEquity rated Buy Theravance, Inc. (NASDAQ: THRX) on 02/20/2009, when the stock price was $14.63. Since
then, Theravance, Inc. has lost 5.54% as of 12/23/2015's recent price of $13.82.
If you would have followed this ThinkEquity's recommendation on THRX, you would have lost 5.53% of your investment in 2497 days.

Theravance, Inc. (Theravance) is a biopharmaceutical company with a pipeline of internally discovered product candidates. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas, including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. Its programs include telavancin for the treatment of serious Gram-positive bacterial infections with Astellas Pharma Inc. (Astellas) and its Horizon program and the Bifunctional Muscarinic Antagonist-beta2 Agonist (MABA) program with GlaxoSmithKline plc (GSK). During the year ended December 31, 2008, Theravance owns 140 issued United States patents and 512 granted foreign patents. In addition, Theravance has 150 United States patent applications pending and 835 foreign patent applications pending as of December 31, 2008.

Research is at the core of everything we do at ThinkEquity, and we're passionate about it. Employing a disciplined and rigorous process, we scrutinize the spectrum of forces at play in the growth sectors we cover. Starting with a top down analysis, we look closely at the megatrends and industry drivers that create opportunities for innovative companies. We then allocate our resources based on a long-range research roadmap that leads to deep domain expertise and a close working knowledge of the technologies, products, services and people that populate the growth sector landscape. In short, the sum result of the ThinkEquity research process is to identify and affiliate ourselves with the fastest growing private and public companies within our domain verticals.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/20/2009 8:25 AM Buy
None
14.63 23.00
as of 12/31/2009
1 Week up  67.16 %
1 Month up  68.31 %
3 Months up  51.29 %
1 YTD up  51.40 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy